blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3782645

EP3782645 - ANTICANCER T CELL THERAPY PRODUCT-ASSISTING COMPOSITION COMPRISING DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY AND USE THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  22.01.2021
Database last updated on 15.06.2024
FormerThe international publication has been made
Status updated on  25.10.2019
Most recent event   Tooltip19.04.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
National Cancer Center
Madu-dong
323 Ilsan-ro
Ilsandong-gu
Goyang-si, Gyeonggi-do 10408 / KR
For all designated states
Eutilex Co., Ltd.
Suite 1401
Daeryung Technotown 17 Cha
25 Gasan Digital 1-ro
Geumcheon-gu
Seoul 08594 / KR
[2021/08]
Inventor(s)01 / CHOI, Beom Kyu
Haesol Maeul 2-danji World Merdian, Mokdong-dong)
208-1502, 347, Waseoksunhwan-ro
Paju-si, Gyeonggi-do 10893 / KR
02 / KIM, Seon Hee
Jeongbalsan-dong) 3rd Floor, 63-29, Ilsan-ro
380beon-gil, Ilsandong-gu
Goyang-si, Gyeonggi-do 10406 / KR
03 / KWON, Byoung Se
Hipark City Ilsan Familie 4-danji, Deogi-dong)
402-2503, 61, Hi park 3-ro, Ilsanseo-gu
Goyang-si, Gyeonggi-do 10235 / KR
04 / KIM, Young Ho
Tanhyeon Maeul 12-danji Apt., Tanhyeon-dong)
1203-1805, 12, Sanhyeon-ro 17beon-gil, Ilsanseo-
gu
Goyang-si, Gyeonggi-do 10344 / KR
 [2021/08]
Representative(s)Dehns
St. Bride's House
10 Salisbury Square
London EC4Y 8JD / GB
[2021/08]
Application number, filing date19788111.311.04.2019
[2021/08]
WO2019KR04349
Priority number, dateKR2018004441117.04.2018         Original published format: KR 20180044411
[2021/08]
Filing languageKO
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019203497
Date:24.10.2019
Language:KO
[2019/43]
Type: A1 Application with search report 
No.:EP3782645
Date:24.02.2021
Language:EN
[2021/08]
Search report(s)International search report - published on:KR24.10.2019
(Supplementary) European search report - dispatched on:EP15.12.2021
ClassificationIPC:A61K39/395, C07K16/28, A61K31/664, A61K31/675, A61K31/7076, A61K35/17, A61K38/20, A61N5/00, A61P35/00, A61P37/02
[2022/02]
CPC:
A61K45/06 (EP); A61K39/395 (KR); A61K35/17 (US);
A61K31/664 (KR); A61K31/675 (EP,US); A61K31/7076 (EP,KR,US);
A61K38/2013 (EP,US); A61K39/3955 (EP); A61K39/4611 (EP,KR);
A61K39/464492 (EP,KR); A61P35/00 (EP,KR,US); A61P37/02 (EP);
C07K16/2812 (EP,US); A61K2035/124 (EP); A61K2039/505 (EP);
A61K2039/545 (EP); A61K2039/585 (EP); A61K2239/31 (EP,KR);
A61K2239/38 (EP,KR); A61K2239/57 (EP,KR); C07K2317/73 (EP) (-)
C-Set:
A61K31/675, A61K2300/00 (EP);
A61K31/7076, A61K2300/00 (EP);
A61K38/2013, A61K2300/00 (EP);
A61K39/3955, A61K2300/00 (EP);
A61K39/464492, A61K2300/00 (EP,KR)
(-)
Former IPC [2021/08]A61K39/395, A61K31/664, A61K31/7076, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/08]
TitleGerman:ZUSAMMENSETZUNG ZUR UNTERSTÜTZUNG VON ANTI-KREBS-T-ZELL-THERAPIEPRODUKT MIT ABREICHERNDEM MONOKLONALEN ANTI-CD4-ANTIKÖRPER UND VERWENDUNG DAVON[2021/08]
English:ANTICANCER T CELL THERAPY PRODUCT-ASSISTING COMPOSITION COMPRISING DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY AND USE THEREOF[2021/08]
French:COMPOSITION D'ASSISTANCE DE PRODUIT DE THÉRAPIE ANTICANCÉREUSE PAR LYMPHOCYTES T COMPRENANT UN ANTICORPS MONOCLONAL ANTI-CD4 INDUISANT LA DÉPLÉTION DES LYMPHOCYTES CD4+ ET SON UTILISATION[2021/08]
Entry into regional phase04.11.2020Translation filed 
04.11.2020National basic fee paid 
04.11.2020Search fee paid 
04.11.2020Designation fee(s) paid 
04.11.2020Examination fee paid 
Examination procedure04.11.2020Examination requested  [2021/08]
21.07.2022Amendment by applicant (claims and/or description)
Fees paidRenewal fee
22.04.2021Renewal fee patent year 03
16.03.2022Renewal fee patent year 04
19.04.2023Renewal fee patent year 05
18.04.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]WO2008003473  (MERCK PATENT GMBH [DE], et al) [Y] 1-7,13-15 * example 9 *;
 [XY]  - WEIQING JING ET AL, "Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory", BLOOD, US, (20090430), vol. 113, no. 18, doi:10.1182/blood-2008-11-190827, ISSN 0006-4971, pages 4449 - 4457, XP055493212 [X] 8-12 * the whole document * [Y] 1-7,13-15

DOI:   http://dx.doi.org/10.1182/blood-2008-11-190827
 [A]  - MOTOYOSHI YASUHIDE ET AL, "Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide.", ONCOLOGY REPORTS, (2006), vol. 16, pages 141 - 146, XP055869250 [A] 1-15 * abstract *
 [T]  - KIM SEON-HEE ET AL, "Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18R[alpha]hi CD8+ T cells", NATURE COMMUNICATIONS, vol. 12, no. 1, doi:10.1038/s41467-021-25559-7, (20210907), URL: https://www.nature.com/articles/s41467-021-25559-7, XP055869243 [T] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1038/s41467-021-25559-7
International search[A]JP3168005B  (UNIVERSITY COLLEGE LONDON)[A] 12-20;
 [A]KR20070098475  (UNIV ULSAN FOUND FOR IND COOP [KR]) [A] 12-20;
 [A]KR20080112300  (GENENTECH INC [US]) [A] 12-20;
 [XY]  - JING, W, "Depletion of CD 4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory", Blood, (20090000), vol. 113, no. 18, doi:10.1182/blood-2008-11-190827, pages 4449 - 4457, XP055493212 [X] 12-17 * 4449, 4450, 4453; 4 * [Y] 18-20

DOI:   http://dx.doi.org/10.1182/blood-2008-11-190827
 [Y]  - JACKAMAN, C., "IL -2 Intratumoral Immunotherapy Enhances CD 8+ T Cells That Mediate Destruction of Tumor Cells and Tumor-Associated Vasculature: A Novel Mechanism for IL -2", The Journal of Immunology, (20030000), vol. 171, no. 10, pages 5051 - 5063, XP055644966 [Y] 18-20 * 4449 *

DOI:   http://dx.doi.org/10.4049/jimmunol.171.10.5051
 [A]  - MAHNKE, K., "Opening a Niche for Therapy: Local Lymphodepletion Helps the Immune System to Fight Melanoma", Journal of Investigative Dermatology, (20140000), vol. 134, no. 7, pages 1794 - 1796, XP055644968 [A] 12-20

DOI:   http://dx.doi.org/10.1038/jid.2014.100
 [A]  - SCHNIZLEIN-BICK, C., "Effects of CD 4 and CD 8 T lymphocyte depletion on the course of histoplasmosis following pulmonary challenge", Medical Mycology, (20030000), vol. 41, no. 3, doi:10.1080/1369378031000137279, pages 189 - 197, XP055644984 [A] 12-20

DOI:   http://dx.doi.org/10.1080/1369378031000137279
by applicantKR101503341B
 KR20180044411
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.